The High-Stakes Battle for Gland Pharma: A Pivotal Shift in Global Pharma Manufacturing

Fosun’s decision to exit Gland Pharma comes at a time when scrutiny of China-dependent supply chains has never been higher. Acquiring Gland Pharma represents more than just buying a profitable CDMO (Contract Development and Manufacturing Organization)—it’s a strategic move to fortify pharma manufacturing outside of China.